BioLine RX LtdNASDAQ:BLRXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.6988
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 0.6988
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BLRX |
|---|---|---|
| 09:32 ET | 290 | 0.73 |
| 09:36 ET | 1750 | 0.75 |
| 09:52 ET | 400 | 0.7217 |
| 09:56 ET | 500 | 0.724999 |
| 09:57 ET | 945 | 0.71 |
| 10:01 ET | 44437 | 0.7 |
| 10:03 ET | 193 | 0.7354 |
| 10:12 ET | 9995 | 0.7 |
| 10:14 ET | 1050 | 0.717551 |
| 10:15 ET | 13291 | 0.7 |
| 10:21 ET | 570 | 0.7199 |
| 10:24 ET | 330 | 0.710051 |
| 10:28 ET | 15345 | 0.69 |
| 10:37 ET | 13700 | 0.6951 |
| 10:42 ET | 250 | 0.7029 |
| 10:48 ET | 2000 | 0.709 |
| 10:50 ET | 500 | 0.709 |
| 10:51 ET | 10220 | 0.696 |
| 10:57 ET | 100 | 0.691791 |
| 11:00 ET | 2127 | 0.69 |
| 11:06 ET | 3900 | 0.681 |
| 11:13 ET | 100 | 0.687201 |
| 11:15 ET | 312 | 0.6897 |
| 11:18 ET | 2000 | 0.6873 |
| 11:20 ET | 200 | 0.6873 |
| 11:22 ET | 11255 | 0.6895 |
| 11:24 ET | 100 | 0.6895 |
| 11:29 ET | 1106 | 0.71 |
| 11:44 ET | 800 | 0.7 |
| 11:56 ET | 150 | 0.7001 |
| 12:02 ET | 265 | 0.72 |
| 12:50 ET | 100 | 0.7002 |
| 01:08 ET | 1700 | 0.7001 |
| 01:12 ET | 120 | 0.7199 |
| 01:19 ET | 2700 | 0.7001 |
| 01:24 ET | 141 | 0.70995 |
| 01:44 ET | 400 | 0.71 |
| 01:50 ET | 200 | 0.70555 |
| 01:51 ET | 100 | 0.7099 |
| 02:04 ET | 100 | 0.7012 |
| 02:18 ET | 4223 | 0.7012 |
| 02:20 ET | 11600 | 0.695 |
| 02:24 ET | 200 | 0.699899 |
| 02:29 ET | 1800 | 0.697 |
| 02:36 ET | 13570 | 0.6998 |
| 02:38 ET | 600 | 0.6998 |
| 02:40 ET | 1200 | 0.6998 |
| 02:42 ET | 1200 | 0.6998 |
| 02:44 ET | 2100 | 0.6997 |
| 02:45 ET | 1800 | 0.694899 |
| 02:47 ET | 1000 | 0.6949 |
| 02:49 ET | 3675 | 0.6994 |
| 02:56 ET | 310 | 0.700024 |
| 03:00 ET | 1000 | 0.7 |
| 03:02 ET | 800 | 0.701861 |
| 03:03 ET | 7926 | 0.7008 |
| 03:05 ET | 1100 | 0.699699 |
| 03:07 ET | 4062 | 0.697 |
| 03:09 ET | 2350 | 0.7024 |
| 03:21 ET | 143 | 0.7024 |
| 03:30 ET | 4700 | 0.6901 |
| 03:45 ET | 1998 | 0.7024 |
| 03:56 ET | 2700 | 0.7024 |
| 03:57 ET | 18779 | 0.7022 |
| 03:59 ET | 4820 | 0.69875 |
Jun 3, 2024
DJ BioLine RX Price Target Maintained With a $21.00/Share by HC Wainwright & Co., from 12:45PM ET on Monday Jun 03, 2024 by Dow Jones
12:45PM ET on Monday Jun 03, 2024 by Dow Jones
May 30, 2024
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD), from 7:00AM ET on Thursday May 30, 2024 by Dow Jones
7:00AM ET on Thursday May 30, 2024 by Dow Jones
May 29, 2024
DJ BioLine RX Price Target Maintained With a $21.00/Share by HC Wainwright & Co., from 10:34AM ET on Wednesday May 29, 2024 by Dow Jones
10:34AM ET on Wednesday May 29, 2024 by Dow Jones
May 28, 2024
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates, from 7:00AM ET on Tuesday May 28, 2024 by Dow Jones
7:00AM ET on Tuesday May 28, 2024 by Dow JonesPress Release: BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates, from 7:00AM ET on Tuesday May 28, 2024 by Dow Jones
7:00AM ET on Tuesday May 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
BioLine RX Ltd | 58.4M | -0.9x | --- |
LAVA Therapeutics NV | 59.4M | -2.2x | --- |
Dyadic International Inc | 63.7M | -7.9x | --- |
Kronos Bio Inc | 47.5M | -0.4x | --- |
Kezar Life Sciences Inc | 50.5M | -0.5x | --- |
Cue Biopharma Inc | 79.3M | -1.5x | --- |
Company Information
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Contact Information
- Headquarters
- Modi'in Technology Park 2 HaMa'ayan StreetMODIIN, Israel 7177871
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board
- Aharon Schwartz
- Chief Executive Officer
- Philip Serlin
- Chief Financial Officer
- Mali Zeevi
- Vice President - Development
- Ella Sorani
- Vice President-Clinical & Medical Affairs
- Abi Vainstein-Haras
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $58.4M |
|---|---|
Revenue (TTM) | $11.7M |
Shares Outstanding | 79.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.54 |
EPS | $-0.76 |
Book Value | $0.18 |
P/E Ratio | -0.9x |
Price/Sales (TTM) | 5.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -391.76% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
